McKesson Corporation: How Are They Benefitting From The GLP-1 Demand Tailwinds?

McKesson Corporation’s second quarter fiscal 2026 earnings report demonstrates both impressive financial performance and strategic alignment with growth-oriented market segments. Consolidated revenues increased 10% year-over-year to $103 billion, and adjusted earnings per diluted share grew by 39% to $9.86, showcasing the company’s ability to sustain momentum and effectively execute its strategic priorities. In response to this robust performance, McKesson raised its annual guidance for adjusted earnings per diluted share to $38.35-$38.85. The company is experiencing significant growth through its oncology and multispecialty segment, underscoring its focus on higher-growth, higher-margin markets. This segment saw a 32% increase in revenue to $12 billion, propelled by expanded distribution and strategic acquisitions such as PRISM Vision and Core Ventures. Operating profit in this segment rose by 71% to $397 million, highlighting strong demand for specialty distribution and oncology products.